As of 2026-09-10, the EV/EBITDA ratio of Trillium Therapeutics Inc (TRIL.TO) is -43.32. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TRIL.TO's latest enterprise value is 2,477.38 mil CAD. TRIL.TO's TTM EBITDA according to its financial statements is -57.19 mil CAD. Dividing these 2 quantities gives us the above TRIL.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 46.6x - 64.5x | 58.3x |
| Forward P/E multiples | 19.8x - 29.1x | 24.8x |
| Fair Price | (32.03) - (19.53) | (28.41) |
| Upside | -237.3% - -183.7% | -221.8% |
| Date | EV/EBITDA |